Ling Bi

812 total citations
29 papers, 569 citations indexed

About

Ling Bi is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Ling Bi has authored 29 papers receiving a total of 569 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 9 papers in Pulmonary and Respiratory Medicine and 9 papers in Oncology. Recurrent topics in Ling Bi's work include Lung Cancer Treatments and Mutations (7 papers), RNA modifications and cancer (5 papers) and Ubiquitin and proteasome pathways (4 papers). Ling Bi is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), RNA modifications and cancer (5 papers) and Ubiquitin and proteasome pathways (4 papers). Ling Bi collaborates with scholars based in China, Australia and South Korea. Ling Bi's co-authors include Sadanobu Kagamimori, Lijing Jiao, Xiulan Su, Toyomi Kuwamori, Ling Xu, Yabin Gong, Jialin Yao, Yan Lu, Qihan Dong and Chanlu Xie and has published in prestigious journals such as Cancer Research, Oncogene and Scientific Reports.

In The Last Decade

Ling Bi

26 papers receiving 559 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ling Bi China	14	262	100	100	88	87	29	569
Xiao-Huang Xu Macao	10	346 1.3×	63 0.6×	54 0.5×	52 0.6×	52 0.6×	13	519
Yifang Li China	13	207 0.8×	27 0.3×	82 0.8×	42 0.5×	58 0.7×	28	566
Maleppillil Vavachan Vijayakumar India	11	246 0.9×	52 0.5×	114 1.1×	50 0.6×	134 1.5×	14	590
Zequn Jiang China	12	281 1.1×	91 0.9×	89 0.9×	55 0.6×	62 0.7×	20	528
Jung Yoon Jang South Korea	15	263 1.0×	27 0.3×	64 0.6×	139 1.6×	86 1.0×	22	571
Manal F. Ismail Egypt	15	236 0.9×	27 0.3×	92 0.9×	44 0.5×	80 0.9×	28	577
Yuan‐Chiang Chung Taiwan	18	310 1.2×	82 0.8×	86 0.9×	41 0.5×	212 2.4×	35	778
Jin-Ming Hwang Taiwan	15	322 1.2×	41 0.4×	88 0.9×	98 1.1×	57 0.7×	20	588
Zhu-Jun Mao China	15	251 1.0×	27 0.3×	84 0.8×	46 0.5×	86 1.0×	39	554

Countries citing papers authored by Ling Bi

Since Specialization

Citations

This map shows the geographic impact of Ling Bi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ling Bi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ling Bi more than expected).

Fields of papers citing papers by Ling Bi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ling Bi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ling Bi. The network helps show where Ling Bi may publish in the future.

Co-authorship network of co-authors of Ling Bi

This figure shows the co-authorship network connecting the top 25 collaborators of Ling Bi. A scholar is included among the top collaborators of Ling Bi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ling Bi. Ling Bi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Sheng, et al.. (2025). B lymphocytes and hyperglycemia synergistically exacerbate coronary in-stent restenosis. International Journal of Cardiology Cardiovascular Risk and Prevention. 29. 200475–200475.

Zhao, Yiyang, et al.. (2025). Thlaspi arvense suppresses gut microbiota related TNF inflammatory pathway to alleviates ulcerative colitis. Frontiers in Immunology. 16. 1537325–1537325.

Wang, Ziwei, et al.. (2024). Traditional Chinese Medicine in Regulating Tumor Microenvironment. OncoTargets and Therapy. Volume 17. 313–325. 7 indexed citations

Zhao, Wei, Ying Cheng, Lei Shi, et al.. (2024). Efficacy and safety of chemotherapy combined with iodine-125 seed brachytherapy for intermediate and advanced oncogenic driver gene-negative non-small cell lung cancer. Brachytherapy. 24(1). 92–102.

Wang, Cheng, Minghao Zhang, Shunyao Li, et al.. (2024). A phosphoglycerate mutase 1 allosteric inhibitor restrains TAM-mediated colon cancer progression. Acta Pharmaceutica Sinica B. 14(11). 4819–4831. 2 indexed citations

Xu, Yichun, Yong Yang, Jun Su, et al.. (2023). Molecular fingerprints of nuclear genome and mitochondrial genome for early diagnosis of lung adenocarcinoma. Journal of Translational Medicine. 21(1). 250–250. 1 indexed citations

Wang, Qin, Lijing Jiao, Ling Bi, et al.. (2023). Intrapleural injection of brucea javanica oil emulsion provided a long-term benefits in patient with malignant pleural effusion from pleural mesothelioma: A case report. EXPLORE. 20(1). 126–129. 2 indexed citations

Zhou, Ye, Cheng Wang, Ya‐Bin Tang, et al.. (2022). Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma. Cancer Research. 82(19). 3516–3531. 42 indexed citations

Yao, Jialin, Yan Lu, Lijing Jiao, et al.. (2022). Chinese Herbal Medicine (Yiqi-Yangyin-Jiedu Decoction) Combined With Osimertinib as First-Line Treatment in EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (CATLA-2): A Study Protocol for a Double-Blind Randomized Controlled Trial. Frontiers in Pharmacology. 13. 840889–840889. 1 indexed citations

10.

Jiang, Jingjie, et al.. (2022). Feiyanning formula modulates the molecular mechanism of osimertinib resistance in lung cancer by regulating the Wnt/β-catenin pathway. Frontiers in Pharmacology. 13. 1019451–1019451. 5 indexed citations

11.

Jiao, Lijing, et al.. (2021). Anticancer Action of Xiaoxianxiong Tang in Non-Small Cell Lung Cancer by Pharmacological Analysis and Experimental Validation. Evidence-based Complementary and Alternative Medicine. 2021. 1–20. 2 indexed citations

12.

Yang, Wenxiao, Ling Bi, Yichao Wang, et al.. (2021). MiR-182-5p promotes the Metastasis and Epithelial-mesenchymal Transition in Non-small Cell Lung Cancer by Targeting EPAS1. Journal of Cancer. 12(23). 7120–7129. 24 indexed citations

13.

Wang, Qin, Lijing Jiao, Shengfei Wang, et al.. (2020). Adjuvant Chemotherapy with Chinese Herbal Medicine Formulas Versus Placebo in Patients with Lung Adenocarcinoma after Radical Surgery: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Biological Procedures Online. 22(1). 16 indexed citations

14.

Zhao, Bei, Xiaodan Hui, Lijing Jiao, et al.. (2020). A TCM Formula YYWY Inhibits Tumor Growth in Non-Small Cell Lung Cancer and Enhances Immune-Response Through Facilitating the Maturation of Dendritic Cells. Frontiers in Pharmacology. 11. 798–798. 29 indexed citations

15.

Jiao, Lijing, Jianfang Xu, Jianli Sun, et al.. (2019). Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Frontiers in Pharmacology. 10. 732–732. 41 indexed citations

16.

Bi, Ling, Chanlu Xie, Yao Mu, et al.. (2018). The histone chaperone complex FACT promotes proliferative switch of G₀ cancer cells. International Journal of Cancer. 145(1). 164–178. 23 indexed citations

17.

Jiao, Lijing, Ling Bi, Yan Lu, et al.. (2018). Cancer chemoprevention and therapy using chinese herbal medicine. Biological Procedures Online. 20(1). 1–1. 46 indexed citations

18.

Wang, Qin, Lijing Jiao, Shengfei Wang, et al.. (2018). Maintenance Chemotherapy With Chinese Herb Medicine Formulas vs. With Placebo in Patients With Advanced Non-small Cell Lung Cancer After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind Trial. Frontiers in Pharmacology. 9. 1233–1233. 25 indexed citations

19.

Que, Zujun, Yuanhong Zheng, Ling Bi, et al.. (2014). Ganoderic acid Me induces the apoptosis of competent T cells and increases the proportion of Treg cells through enhancing the expression and activation of indoleamine 2,3-dioxygenase in mouse lewis lung cancer cells. International Immunopharmacology. 23(1). 192–204. 26 indexed citations

20.

Bi, Ling, et al.. (2003). Beneficial effects of taurine on serum lipids in overweight or obese non-diabetic subjects. Amino Acids. 26(3). 267–71. 157 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact